In a trial of 2,175 people with early HER2-positive breast cancer, 43.8% had no invasive cancer left after 12 weeks of a lighter regimen, and certain tumor features predicted who was most likely to respond.
|Articles|October 13, 2019
Metastatic Breast Cancer Awareness Day: What You Need to Know
Author(s)Jessica Skarzynski
For Metastatic Breast Cancer Awareness Day on October 13th, 2019, here’s a round-up of fast facts and the latest news and updates in this disease space.
Advertisement
For Metastatic Breast Cancer Awareness Day on October 13th, 2019, here’s a round-up of fast facts and the latest news and updates in this disease space:
- Three-time cancer survivor and one-woman show writer and performer, Valerie David, sat down with CURE to discuss her experiences with non-Hodgkin lymphoma, then stage 2 breast cancer and, most recently, metastatic stage 4 breast cancer.
- After being diagnosed with metastatic breast cancer in January 2015, CURE contributor Martha Carlson shares some tips on how to responsibly search for healthcare information online.
- The Food and Drug Administration recently approved Piqray (alpelisib) for the treatment of certain postmenopausal women, and men, with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer.
- Eight-year metastatic “thriver” Stephanie Seban explains the hurdles she faced as she received the wrong treatment for nearly five years.
- In another FDA action, the subcutaneous use of Herceptin and Herceptin Hylecta in combination with chemotherapy was approved for the treatment of select patients with breast cancer.
Advertisement
Related to this article
Median progression-free survival reached 24.9 months with Tukysa plus Herceptin and Perjeta versus 16.3 months with placebo plus Herceptin and Perjeta.
Breast cancer survivor Sue Weldon discusses survivorship gaps, integrative therapies alongside treatment and why caregivers should prioritize themselves.
Endoscopic nipple-sparing mastectomy may improve recovery, reduce scarring and support quality of life for people undergoing breast cancer surgery.
Learn how nipple-sparing mastectomy, including endoscopic approaches, may help preserve appearance, reduce scarring and support breast cancer recovery.
After 17 and a half years with metastatic primary peritoneal cancer, a former hospital executive explains how an AI health agent helped her after discharge.
Giredestrant plus Afinitor lowered the risk of cancer worsening or death by 62% in patients with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer.
A study of more than 17,000 patients ages 23 to 64, presented at ASTRO 2026, found that only about 28% took endocrine therapy consistently for five years, and people who skipped radiation were more likely to fall off. Here's what to weigh before making that choice.
Advertisement
Advertisement
Trending on CURE
1
Why PSA Monitoring Matters After a Prostate Cancer Diagnosis
2
FDA Withdraws Zepzelca Approval for Previously Treated Small Cell Lung Cancer
3
Life After Cancer: Challenge Yourself to Build Healthier Habits and Stronger Relationships
4
The Cancer Search Bar: Top Lung Cancer Surgery Questions Answered
5